Nektar Therapeutics (NKTR) Non-Current Assets (2010 - 2026)

Nektar Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $174.2 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 561.77% year-over-year to $174.2 million; the TTM figure through Mar 2026 stood at $229.3 million (up 65.56% YoY), while the FY2025 annual figure was $14.1 million, down 66.77% from the prior year.
• Non-Current Assets for Q1 2026 stood at $174.2 million, up from $14.1 million in the prior quarter.
• The five-year high for Non-Current Assets was $290.7 million in Q1 2022, with the low at $14.1 million in Q4 2025.
• The 5-year median for Non-Current Assets is $53.2 million (2023), against an average of $88.9 million.
• The sharpest annual moves came in 2023 and 2026: Non-Current Assets tumbled 76.19% in 2023, then surged 561.77% in 2026.
• Nektar Therapeutics' Non-Current Assets stood at $164.6 million in 2022, then tumbled by 59.1% to $67.3 million in 2023, then slumped by 36.79% to $42.6 million in 2024, then plunged by 66.77% to $14.1 million in 2025, then soared by 1132.18% to $174.2 million in 2026.
• Business Quant data shows NKTR's Non-Current Assets at $174.2 million in Q1 2026, $14.1 million in Q4 2025, and $20.0 million in Q3 2025.